{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:40:22Z","timestamp":1782376822202,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.intimp.2022.108709","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T01:29:12Z","timestamp":1647566952000},"page":"108709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-9343","authenticated-orcid":false,"given":"Luca","family":"Masotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Landini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Panigada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Tarquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Maria Angela","family":"Cimolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vieri","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Piani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fortini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Faraone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Nenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cipollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Risaliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Aquilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Seravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bribani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Farsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pelagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mattaliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Maria","family":"Madonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Mannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Valoriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Brancati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rosselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Burla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.108709_b0005","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1080\/21655979.2022.2031417","article-title":"COVID-19 in Southeast Asia: current status and perspectives","volume":"13","author":"Chu","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.intimp.2022.108709_b0010","article-title":"The emergence of the omicron (B.1.1.529) SARS-CoV-2 variant: what is the impact on the continued pandemic?","volume":"1\u20134","author":"Al-Tawfiq","year":"2022","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"1","key":"10.1016\/j.intimp.2022.108709_b0015","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13429","article-title":"Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis","volume":"51","author":"Mulchandani","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2022.108709_b0020","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"Osuchowski","year":"2021","journal-title":"Lancet Respir Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.108709_b0025","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jinf.2020.06.008","article-title":"Interleukin-6 as prognosticator in patients with COVID-19","volume":"81","author":"Grifoni","year":"2020","journal-title":"J. Infect."},{"issue":"4","key":"10.1016\/j.intimp.2022.108709_b0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12291-021-00989-8","article-title":"Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm","volume":"36","author":"Shekhawat","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"issue":"6","key":"10.1016\/j.intimp.2022.108709_b0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","article-title":"Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19","volume":"51","author":"Saha","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.intimp.2022.108709_b0040","doi-asserted-by":"crossref","first-page":"108536","DOI":"10.1016\/j.intimp.2022.108536","article-title":"An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)","volume":"105","author":"Elahi","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108709_b0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jinf.2021.11.013","article-title":"Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: a systematic review and meta-analysis","volume":"84","author":"Luo","year":"2022","journal-title":"J. Infect."},{"issue":"3","key":"10.1016\/j.intimp.2022.108709_b0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40121-021-00488-6","article-title":"HNF Hospital tocilizumab multidisciplinary team. Systematic review and subgroup meta-analysis of randomized trials to determine Tocilizumab's place in COVID-19 pneumonia","volume":"10","author":"Klopfenstein","year":"2021","journal-title":"Infect. Dis. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.108709_b0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2021.11.007","article-title":"ESCMID COVID-19 living guidelines: drug treatment and clinical management","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.intimp.2022.108709_b0060","unstructured":"https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/ IDSA Guidelines on the Treatment and Management of Patients with COVID-19 Published by IDSA on 4\/11\/2020. Last updated, 1\/18\/2022."},{"issue":"1491\u20131502","key":"10.1016\/j.intimp.2022.108709_b0065","article-title":"Interleukin-6 receptor antagonists in critically Ill patients with Covid-19","volume":"384","author":"REMAP-CAP Investigators","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10285","key":"10.1016\/j.intimp.2022.108709_b0070","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2022.108709_b0075","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.intimp.2022.108709_b0080","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-use-roactemra-adults-severe-covid-19."},{"key":"10.1016\/j.intimp.2022.108709_b0085","unstructured":"https:\/\/www.aifa.gov.it\/-\/utilizzo-di-tocilizumab-per-la-terapia-dei-pazienti-affetti-da-covid-19."},{"key":"10.1016\/j.intimp.2022.108709_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcrc.2021.05.007","article-title":"Mortality and clinical outcomes in patients with COVID-19 pneumonia treated with non-invasive respiratory support: a rapid review","volume":"65","author":"Radovanovic","year":"2021","journal-title":"J. Crit. Care"},{"issue":"7","key":"10.1016\/j.intimp.2022.108709_b0095","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","volume":"2","author":"McGonagle","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108709_b0100","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.intimp.2022.108709_b0105","article-title":"Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era","volume":"8","author":"Campbell","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.intimp.2022.108709_b0110","doi-asserted-by":"crossref","first-page":"e0247461","DOI":"10.1371\/journal.pone.0247461","article-title":"Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis","volume":"16","author":"Booth","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108709_b0115","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie","year":"2021","journal-title":"BMC Infect. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2022.108709_b0120","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1093\/cid\/ciaa1012","article-title":"Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET)","volume":"72","author":"Kim","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2022.108709_b0125","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamainternmed.2020.3539","article-title":"COVID-19 lombardy ICU network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy","volume":"180","author":"Grasselli","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.108709_b0130","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial","volume":"47","author":"Rosas","year":"2021","journal-title":"Intensive Care Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.108709_b0135","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","article-title":"Co-infections in people with COVID-19: a systematic review and meta-analysis","volume":"81","author":"Lansbury","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.intimp.2022.108709_b0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-030-59261-5_25","article-title":"The Level of Procalcitonin in severe COVID-19 patients: a systematic review and meta-analysis","volume":"1321","author":"Heidari-Beni","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108709_b0145","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jiac.2021.05.007","article-title":"Tocilizumab in COVID-19: the cerrahpa\u015fa-PREDICT score","volume":"27","author":"E\u015fkazan","year":"2021","journal-title":"J. Infect. Chemother"},{"issue":"2","key":"10.1016\/j.intimp.2022.108709_b0150","doi-asserted-by":"crossref","first-page":"e0247275","DOI":"10.1371\/journal.pone.0247275","article-title":"Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection","volume":"16","author":"Mussini","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108709_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.620187","article-title":"Tocilizumab in COVID-19: factors associated with mortality before and after treatment","volume":"12","author":"Sarabia De Ardanaz","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108709_b0160","first-page":"e13116","article-title":"Predictors of mortality amongst tocilizumab administered COVID-19 Asian Indians: a predictive study from a tertiary care centre","volume":"13","author":"Desai","year":"2021","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.intimp.2022.108709_b0165","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.micinf.2020.06.005","article-title":"Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)","volume":"22","author":"Lohse","year":"2020","journal-title":"Microbes Infect."},{"issue":"2","key":"10.1016\/j.intimp.2022.108709_b0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/17512433.2021.1875819","article-title":"Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain","volume":"14","author":"Chamorro-de-Vega","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108709_b0175","doi-asserted-by":"crossref","DOI":"10.1556\/030.2021.01526","article-title":"Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab","author":"Lakatos","year":"2021","journal-title":"Acta Microbiol. Immunol. Hung."},{"issue":"6","key":"10.1016\/j.intimp.2022.108709_b0180","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1473-3099(21)00019-0","article-title":"REIPI-SEIMC COVID-19 group and COVID@HULP groups. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study","volume":"21","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2022.108709_b0185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00134-020-06033-2","article-title":"COVID-19 pneumonia: different respiratory treatments for different phenotypes?","volume":"46","author":"Gattinoni","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.intimp.2022.108709_b0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijid.2021.02.041","article-title":"Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study","volume":"105","author":"de la Calle","year":"2021","journal-title":"Int J Infect Dis"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:40:49Z","timestamp":1761586849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692200193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"alternative-id":["S156757692200193X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108709","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108709"}}